Target intelligence / Profile preview

TOM1-like protein 2 (TOM1L2)

Target
TOM1L2
Molecular classification
Adaptor protein, Vesicular trafficking protein, Endosomal trafficking protein, ESCRT-associated protein, Clathrin-binding protein
01

Overview

TOM1-like protein 2 (TOM1L2) is a human adaptor protein encoded by the TOM1L2 gene. It contains an N-terminal VHS domain, a GAT domain, and a C-terminal clathrin-binding motif, enabling TOM1L2 to participate in vesicular trafficking and endosomal sorting. TOM1L2 plays a critical role in ciliary signaling by acting as an adaptor for Lys63-linked ubiquitin chains and the BBSome complex, facilitating the removal of ubiquitinated G protein-coupled receptors from cilia. It colocalizes with Golgi compartments and is believed to regulate growth factor-mediated signaling and immune response. Genetic variants in TOM1L2 are implicated in musculoskeletal traits and disease syndromes such as Smith-Magenis syndrome. Knockdown or loss of TOM1L2 in animal models leads to increased susceptibility to infections, tumor development, splenomegaly, abnormal B- and T-cell counts, and impaired humoral immune responses.

Other names
TOM1L2Target of MYB1-like 2 membrane trafficking proteinTOM1-like protein 2target of myb1-like 2 (chicken)TM1L2_HUMAN (UniProt)
02

Mechanism of action

Not established; theoretically, drugs influencing TOM1L2 would affect vesicular trafficking, GPCR signaling, and immune response modulation.

03

Biological functions

Protein transportIntracellular protein traffickingEndosomal sortingSignal transductionRegulation of ciliary receptor retrieval (GPCRs)Immune response regulationAutophagy
04

Disease associations

Cancer/tumor suppressionImmune system dysfunctionInfection susceptibilitySmith-Magenis syndromeMusculoskeletal traitsPatella, chondromalacia
05

Safety considerations

Potential risk of immunosuppression, increased infection, and tumor formation when TOM1L2 is disruptedInhibition may have broad cellular effects due to its housekeeping roles
06

Interacting drugs

None specifically annotated
07

Biomarkers

Expression of TOM1L2 (gene/protein) in certain cancers, immunological dysfunction, or Smith-Magenis syndromeNot commonly used in clinical settings yet

Beyond the preview

Go deeper on TOM1-like protein 2 (TOM1L2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOM1-like protein 2 (TOM1L2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call